TN2017000508A1 - 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor - Google Patents
2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptorInfo
- Publication number
- TN2017000508A1 TN2017000508A1 TNP/2017/000508A TN2017000508A TN2017000508A1 TN 2017000508 A1 TN2017000508 A1 TN 2017000508A1 TN 2017000508 A TN2017000508 A TN 2017000508A TN 2017000508 A1 TN2017000508 A1 TN 2017000508A1
- Authority
- TN
- Tunisia
- Prior art keywords
- receptor
- benzoxazin
- modulators
- dihydro
- derivatives
- Prior art date
Links
- 102000007207 Muscarinic M1 Receptor Human genes 0.000 title abstract 2
- 108010008406 Muscarinic M1 Receptor Proteins 0.000 title abstract 2
- 230000001713 cholinergic effect Effects 0.000 title abstract 2
- YBYIZRPBXCCDQW-UHFFFAOYSA-N 2,3-dihydro-1,3-benzoxazin-4-one Chemical class C1=CC=C2C(=O)NCOC2=C1 YBYIZRPBXCCDQW-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 abstract 1
- 201000002832 Lewy body dementia Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229940126027 positive allosteric modulator Drugs 0.000 abstract 1
- 229940043274 prophylactic drug Drugs 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 208000020685 sleep-wake disease Diseases 0.000 abstract 1
- 229940126585 therapeutic drug Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
- C07D265/22—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
- C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015129043 | 2015-06-26 | ||
| JP2015206797 | 2015-10-20 | ||
| PCT/JP2016/069189 WO2016208775A1 (en) | 2015-06-26 | 2016-06-23 | 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2017000508A1 true TN2017000508A1 (en) | 2019-04-12 |
Family
ID=56799518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP/2017/000508A TN2017000508A1 (en) | 2015-06-26 | 2016-06-23 | 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US9878989B2 (OSRAM) |
| EP (1) | EP3313836B1 (OSRAM) |
| JP (1) | JP6745824B2 (OSRAM) |
| KR (1) | KR20180019234A (OSRAM) |
| CN (1) | CN107922403A (OSRAM) |
| AU (1) | AU2016284654B9 (OSRAM) |
| CA (1) | CA2988572A1 (OSRAM) |
| CL (1) | CL2017003127A1 (OSRAM) |
| CO (1) | CO2017012859A2 (OSRAM) |
| CR (1) | CR20170568A (OSRAM) |
| DO (1) | DOP2017000309A (OSRAM) |
| EA (1) | EA201890152A1 (OSRAM) |
| HK (1) | HK1248698A1 (OSRAM) |
| IL (1) | IL256059A (OSRAM) |
| MX (1) | MX2017016875A (OSRAM) |
| PE (1) | PE20180500A1 (OSRAM) |
| PH (1) | PH12017502351A1 (OSRAM) |
| TN (1) | TN2017000508A1 (OSRAM) |
| TW (1) | TW201710255A (OSRAM) |
| UA (1) | UA121503C2 (OSRAM) |
| UY (1) | UY36750A (OSRAM) |
| WO (1) | WO2016208775A1 (OSRAM) |
| ZA (1) | ZA201708387B (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20170568A (es) * | 2015-06-26 | 2018-04-20 | Takeda Pharmaceuticals Co | Compuesto heterocíclico |
| WO2016206101A1 (en) | 2015-06-26 | 2016-12-29 | Merck Sharp & Dohme Corp. | Metallo-beta-lactamase inhibitors |
| JP6787913B2 (ja) | 2015-10-20 | 2020-11-18 | 武田薬品工業株式会社 | 複素環化合物 |
| EP3428150B1 (en) | 2016-03-11 | 2023-07-12 | Takeda Pharmaceutical Company Limited | Aromatic ring compound having a cholinergic muscarine m1 receptor positive allosteric modulator activity |
| US10710989B2 (en) * | 2017-02-28 | 2020-07-14 | Takeda Pharmaceutical Company Limited | Method for producing heterocyclic compound |
| JP7145875B2 (ja) * | 2017-04-18 | 2022-10-03 | 武田薬品工業株式会社 | アセチルコリン受容体のモジュレーターとして有用な複素環化合物 |
| EP3627152A4 (en) | 2017-05-19 | 2021-02-24 | Takeda Pharmaceutical Company Limited | Screening method |
| HRP20231236T1 (hr) | 2017-06-20 | 2024-02-16 | Takeda Pharmaceutical Company Limited | Heterociklički spoj i njegova uporaba kao pozitivnog alosteričnog modulatora kolinergičkog muskarinskog m1 receptora |
| JP7123042B2 (ja) | 2017-06-20 | 2022-08-22 | 武田薬品工業株式会社 | 複素環化合物 |
| BR112021005759A2 (pt) * | 2018-09-28 | 2021-07-06 | Takeda Pharmaceuticals Co | composto, medicamento, métodos de modulação alostérica positiva e para a profilaxia ou o tratamento de constipação, e, uso do composto ou de um sal do mesmo |
| WO2020067457A1 (ja) | 2018-09-28 | 2020-04-02 | 武田薬品工業株式会社 | 縮合環化合物 |
| US11970483B2 (en) | 2018-09-28 | 2024-04-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| KR102288434B1 (ko) * | 2018-10-18 | 2021-08-12 | 에이치케이이노엔 주식회사 | 신규한 (이소프로필-트리아졸릴)피리디닐 치환된 벤조옥사지논 또는 벤조티아지논 유도체 및 이의 용도 |
| WO2020086857A1 (en) | 2018-10-24 | 2020-04-30 | Vanderbilt University | Wdr5 inhibitors and modulators |
| US20220242849A1 (en) * | 2019-06-04 | 2022-08-04 | Vanderbilt University | Wdr5 inhibitors and modulators |
| CN114539035B (zh) * | 2021-03-10 | 2023-08-18 | 山东新时代药业有限公司 | 一种七氟烷的合成方法 |
| WO2025231260A1 (en) * | 2024-05-01 | 2025-11-06 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
| WO2025231259A1 (en) * | 2024-05-01 | 2025-11-06 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5538983A (en) | 1990-05-16 | 1996-07-23 | The Rockefeller University | Method of treating amyloidosis by modulation of calcium |
| CA2113115A1 (en) | 1991-07-29 | 1993-02-18 | Vlad E. Gregor | Quinazoline derivatives as acetylcholinesterase inhibitors |
| IT1255179B (it) | 1992-06-26 | 1995-10-20 | Enzo Cereda | Azaciclo e azabiciclo alchiliden idrossilamine |
| US5744476A (en) | 1994-06-27 | 1998-04-28 | Interneuron Pharmaceuticals, Inc. | Dopamine D1 agonists for the treatment of dementia |
| JP2992677B2 (ja) | 1995-06-05 | 1999-12-20 | 武田薬品工業株式会社 | 骨形成促進医薬組成物 |
| AU5716898A (en) | 1997-01-08 | 1998-08-03 | Warner-Lambert Company | Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease |
| CA2317942A1 (en) | 1998-01-16 | 1999-07-22 | Purdue Research Foundation | Alkenyldiarylmethane non-nucleoside hiv-1 reverse transcriptase inhibitors |
| UA59433C2 (uk) | 1998-01-27 | 2003-09-15 | Авентіс Фармасьютікалс Продактс Інк. | ЗАМІЩЕНІ ОКСОАЗАГЕТЕРОЦИКЛІЧНІ ІНГІБІТОРИ ФАКТОРА Хa ТА ПРОМІЖНІ СПОЛУКИ ДЛЯ ЇХ ОТРИМАННЯ |
| WO2000032590A1 (en) | 1998-11-25 | 2000-06-08 | Aventis Pharmaceuticals Products Inc. | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS |
| EP1208097B1 (en) | 1999-07-28 | 2009-02-18 | Aventis Pharmaceuticals Inc. | Substituted oxoazaheterocyclyl compounds |
| JP2001131173A (ja) | 1999-08-23 | 2001-05-15 | Kyorin Pharmaceut Co Ltd | 二環式複素環誘導体 |
| JP2005231995A (ja) | 1999-12-22 | 2005-09-02 | Meiji Seika Kaisha Ltd | オピオイドδ受容体アゴニスト／アンタゴニストとして有用なスピロ化合物 |
| US7084126B1 (en) | 2000-05-01 | 2006-08-01 | Healthpartners Research Foundation | Methods and compositions for enhancing cellular function through protection of tissue components |
| WO2002003684A2 (en) | 2000-06-30 | 2002-01-10 | Eli Lilly And Company | Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist |
| AU2002245692A1 (en) | 2001-03-15 | 2002-10-03 | David Pharmaceuticals | Methods for restoring cognitive function following systemic stress |
| US20040023951A1 (en) | 2001-06-18 | 2004-02-05 | Bymaster Franklin Porter | Combination therapy for treatment of psychoses |
| US20030004913A1 (en) | 2001-07-02 | 2003-01-02 | Koninklijke Philips Electronics N.V. | Vision-based method and apparatus for detecting an event requiring assistance or documentation |
| HUP0402279A3 (en) | 2001-11-26 | 2008-09-29 | Cortex Pharmaceuticals | Heterocondensated benzo[e][1,3]oxazin-4-one compounds for enhancing glutamatergic synaptic responses and pharmaceutical compositions containing them |
| US20040044023A1 (en) | 2002-08-30 | 2004-03-04 | Marc Cantillon | Compositions and methods for treating or preventing memory impairment |
| WO2004073639A2 (en) | 2003-02-19 | 2004-09-02 | Merck & Co. Inc. | Treatment of psychosis with a muscarinic m1 receptor ectopic activator |
| CA2520125A1 (en) | 2003-03-28 | 2004-10-14 | Acadia Pharmaceuticals Inc. | Muscarinic m1 receptor agonists for pain management |
| US20040266659A1 (en) | 2003-06-27 | 2004-12-30 | Stephen LaBerge | Substances that enhance recall and lucidity during dreaming |
| GB0504019D0 (en) | 2005-02-26 | 2005-04-06 | Astrazeneca Ab | Amide derivatives |
| EP1885708A2 (en) | 2005-04-15 | 2008-02-13 | Board of Trustees of Michigan State University | Gpcr modulators |
| GB0516570D0 (en) | 2005-08-12 | 2005-09-21 | Astrazeneca Ab | Amide derivatives |
| US7678363B2 (en) | 2005-08-26 | 2010-03-16 | Braincells Inc | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs |
| US20110319386A1 (en) | 2005-08-26 | 2011-12-29 | Braincells Inc. | Neurogenesis by muscarinic receptor modulation |
| WO2007044937A2 (en) | 2005-10-13 | 2007-04-19 | President And Fellows Of Harvard College | Compositions and methods to modulate memory |
| EP1966214B9 (en) | 2005-12-21 | 2017-09-13 | Janssen Pharmaceutica N.V. | Triazolopyridazines as tyrosine kinase modulators |
| GB0607952D0 (en) | 2006-04-21 | 2006-05-31 | Minster Res Ltd | Novel treatment |
| GB0607946D0 (en) | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
| GB0607949D0 (en) | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
| PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| US8198448B2 (en) | 2006-07-14 | 2012-06-12 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| US7834023B2 (en) | 2006-09-20 | 2010-11-16 | Portola Pharmaceuticals, Inc. | Substituted dihydroquinazolines as platelet ADP receptor inhibitors |
| AP2502A (en) | 2007-01-03 | 2012-10-23 | Servier Lab | 3-substituted-[1,2,3]-benzotriazinone compound forenhancing glutamatergic synaptic responses |
| WO2008113072A2 (en) | 2007-03-15 | 2008-09-18 | Board Of Regents, The University Of Texas System | Gpcr enhanced neuroprotection to treat brain injury |
| ATE541845T1 (de) | 2007-08-29 | 2012-02-15 | Schering Corp | 2,3-substituierte azaindolderivate zur behandlung von virusinfektionen |
| JP5272008B2 (ja) | 2007-08-29 | 2013-08-28 | メルク・シャープ・アンド・ドーム・コーポレーション | 置換インドール誘導体およびその使用の方法 |
| PE20090995A1 (es) | 2007-08-29 | 2009-08-03 | Schering Corp | Derivados indolicos 2,3-sustituidos como inhibidores del virus de la hepatitis c (vhc) |
| NO2200610T3 (OSRAM) | 2007-09-21 | 2018-06-09 | ||
| US20090082342A1 (en) | 2007-09-21 | 2009-03-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
| JP5249344B2 (ja) | 2007-11-16 | 2013-07-31 | メルク・シャープ・アンド・ドーム・コーポレーション | ヘテロ環の３位が置換されたインドール誘導体およびその使用 |
| JP5416708B2 (ja) | 2007-11-16 | 2014-02-12 | メルク・シャープ・アンド・ドーム・コーポレーション | ３−アミノスルホニル置換インドール誘導体およびそれらの使用方法 |
| US20110024198A1 (en) | 2008-02-19 | 2011-02-03 | Baker Hughes Incorporated | Bearing systems containing diamond enhanced materials and downhole applications for same |
| WO2010042603A1 (en) | 2008-10-08 | 2010-04-15 | Cingulate Neuro Therapeutics, Llc | Amyloid and depression |
| WO2010059773A1 (en) * | 2008-11-20 | 2010-05-27 | Merck Sharp & Dohme Corp. | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators |
| US8486946B2 (en) | 2009-02-23 | 2013-07-16 | Merck Sharp & Dohme Corp. | Pyrazolo [4,3-c] cinnolin-3-one M1 receptor positive allosteric modulators |
| JP2012519704A (ja) | 2009-03-05 | 2012-08-30 | ミスリィディオン，インク． | 認知増強用化合物及び組成物、製造法、並びに治療法 |
| EP2421366B1 (en) | 2009-04-20 | 2013-08-28 | Merck Sharp & Dohme Corp. | Heterocyclic fused cinnoline m1 receptor positive allosteric modulators |
| ES2353093B1 (es) | 2009-05-20 | 2012-01-03 | Consejo Superior De Investigaciones Científicas (Csic) | Uso de derivados de quinazolinas y sus composiciones farmacéuticas en enfermedades neurodegenerativas. |
| US10265311B2 (en) | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| DK3061821T3 (da) | 2009-07-22 | 2019-08-26 | PureTech Health LLC | Sammensætninger til behandling af forstyrrelser lindret af muskarinreceptoraktivering |
| CA2770480C (en) | 2009-08-31 | 2014-11-18 | Merck Sharp & Dohme Corp. | Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators |
| EP2490692B1 (en) | 2009-10-21 | 2016-11-16 | Merck Sharp & Dohme Corp. | Quinolinone-pyrazolone m1 receptor positive allosteric modulators |
| EP2512245B1 (en) | 2009-12-14 | 2014-07-23 | Merck Sharp & Dohme Corp. | Pyridoquinazolinone m1 receptor positive allosteric modulators |
| US8383638B2 (en) | 2009-12-21 | 2013-02-26 | Merck Sharp & Dohme | Aminobenzoquinazolinone M1 receptor positive allosteric modulators |
| EP2582241B1 (en) * | 2010-06-15 | 2016-04-06 | Merck Sharp & Dohme Corp. | Heterocyclic fused phenanthrolinone m1 receptor positive allosteric modulators |
| EP2588104B1 (en) | 2010-07-01 | 2014-12-10 | Merck Sharp & Dohme Corp. | Isoindolone m1 receptor positive allosteric modulators |
| WO2012047702A1 (en) * | 2010-10-04 | 2012-04-12 | Merck Sharp & Dohme Corp. | Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators |
| WO2012149524A1 (en) | 2011-04-29 | 2012-11-01 | The University Of Toledo | Muscarinic agonists as enhancers of working memory and cognitive flexibility |
| EP2709624B1 (en) * | 2011-05-17 | 2016-04-27 | Merck Sharp & Dohme Corp. | N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators |
| WO2012170599A1 (en) | 2011-06-10 | 2012-12-13 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| WO2013129622A1 (ja) | 2012-03-02 | 2013-09-06 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| MX358514B (es) | 2012-03-23 | 2018-08-24 | Ptc Therapeutics Inc | Compuestos para tratar la atrofia muscular espinal. |
| US20130289019A1 (en) | 2012-04-26 | 2013-10-31 | Amazing Grace, Inc. | Methods of treating behaviorial and/or mental disorders |
| JP6211530B2 (ja) | 2012-11-19 | 2017-10-11 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
| JP6075408B2 (ja) | 2012-11-22 | 2017-02-08 | 株式会社デンソー | 物標検出装置 |
| KR101685862B1 (ko) | 2012-12-27 | 2016-12-20 | 에프. 호프만-라 로슈 아게 | Comt 억제제 |
| CN104955826B (zh) | 2013-02-04 | 2019-05-31 | 默克专利股份公司 | 可用于治疗神经学疾病和病症的螺-喹唑酮衍生物 |
| US10738024B2 (en) | 2013-05-06 | 2020-08-11 | Indiana University Research And Technology Corporation | Compounds for treatment of angiogenesis-mediated diseases |
| JP6063400B2 (ja) | 2014-01-08 | 2017-01-18 | 株式会社日立ビルシステム | エレベータの異常監視装置 |
| CN106536508B (zh) | 2014-04-23 | 2019-08-09 | 武田药品工业株式会社 | 用于治疗阿尔茨海默病的具有胆碱能毒蕈碱m1受体正变构调节剂活性的化合物 |
| JP6531093B2 (ja) | 2014-05-16 | 2019-06-12 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
| WO2015190564A1 (ja) | 2014-06-13 | 2015-12-17 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
| CR20170568A (es) * | 2015-06-26 | 2018-04-20 | Takeda Pharmaceuticals Co | Compuesto heterocíclico |
| US20180250270A1 (en) | 2015-09-11 | 2018-09-06 | Chase Pharmaceuticals Corporation | Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system |
| JP6787913B2 (ja) | 2015-10-20 | 2020-11-18 | 武田薬品工業株式会社 | 複素環化合物 |
| EP3428150B1 (en) | 2016-03-11 | 2023-07-12 | Takeda Pharmaceutical Company Limited | Aromatic ring compound having a cholinergic muscarine m1 receptor positive allosteric modulator activity |
| EP3562477A4 (en) | 2016-12-29 | 2020-11-18 | Synnerva Ltd. | PROCEDURES AND COMPOSITIONS FOR POTENTIATING CNS DRUGS AND REDUCING THEIR SIDE EFFECTS |
-
2016
- 2016-06-23 CR CR20170568A patent/CR20170568A/es unknown
- 2016-06-23 JP JP2017567489A patent/JP6745824B2/ja active Active
- 2016-06-23 KR KR1020187002502A patent/KR20180019234A/ko not_active Withdrawn
- 2016-06-23 US US15/190,642 patent/US9878989B2/en active Active
- 2016-06-23 UY UY0001036750A patent/UY36750A/es not_active Application Discontinuation
- 2016-06-23 HK HK18108309.9A patent/HK1248698A1/zh unknown
- 2016-06-23 TW TW105119717A patent/TW201710255A/zh unknown
- 2016-06-23 CA CA2988572A patent/CA2988572A1/en not_active Abandoned
- 2016-06-23 EA EA201890152A patent/EA201890152A1/ru unknown
- 2016-06-23 US US15/735,418 patent/US10323027B2/en active Active
- 2016-06-23 WO PCT/JP2016/069189 patent/WO2016208775A1/en not_active Ceased
- 2016-06-23 PE PE2017002792A patent/PE20180500A1/es unknown
- 2016-06-23 UA UAA201800653A patent/UA121503C2/uk unknown
- 2016-06-23 TN TNP/2017/000508A patent/TN2017000508A1/en unknown
- 2016-06-23 AU AU2016284654A patent/AU2016284654B9/en not_active Ceased
- 2016-06-23 EP EP16756814.6A patent/EP3313836B1/en active Active
- 2016-06-23 CN CN201680048681.6A patent/CN107922403A/zh active Pending
- 2016-06-23 MX MX2017016875A patent/MX2017016875A/es unknown
-
2017
- 2017-10-31 US US15/799,379 patent/US10087150B2/en active Active
- 2017-12-03 IL IL256059A patent/IL256059A/en unknown
- 2017-12-07 CL CL2017003127A patent/CL2017003127A1/es unknown
- 2017-12-11 ZA ZA2017/08387A patent/ZA201708387B/en unknown
- 2017-12-14 CO CONC2017/0012859A patent/CO2017012859A2/es unknown
- 2017-12-18 PH PH12017502351A patent/PH12017502351A1/en unknown
- 2017-12-26 DO DO2017000309A patent/DOP2017000309A/es unknown
-
2018
- 2018-08-27 US US16/113,635 patent/US10428056B2/en active Active
-
2019
- 2019-04-25 US US16/394,762 patent/US10899752B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017502351A1 (en) | 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor | |
| MY195742A (en) | Isoindoline-1-One Derivatives as Cholinergic Muscarinic M1 Receptor Positive Alloesteric Modulator Activity for the Treatment of Alzheimers Disease | |
| JO3146B1 (ar) | مشتقات غير متجانسة الحلقية و استخدامها في علاج الاضطرابات العصبية | |
| MX2014006026A (es) | Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2). | |
| GT201400301A (es) | 7h-pirrolo [2,3-d] pirimidinas-4- ( aminho-substituidas) novedosas como inhibidores de lrrk2 | |
| PH12012502373A1 (en) | Aminopyrimidine derivatives as lrrk2 modulators | |
| MX376257B (es) | Moduladores alostericos de receptores de acetilcolina nicotinicos. | |
| PH12013500247A1 (en) | Heterocyclic compound and use thereof | |
| MX348606B (es) | Derivados de aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2). | |
| NZ704863A (en) | Bicyclic pyridinones useful as gamma secretase modulators | |
| MX358172B (es) | Derivados de pirazol aminopirimidina como moduladores de la proteina cinasa 2 de repeticion rica en leucina (lrrk2) para usarse en el tratamiento de la enfermedad de parkinson. | |
| TW201613890A (en) | Pyridine derivatives as muscarinic M1 receptor positive allosteric modulators | |
| GEP20196949B (en) | 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors | |
| MX2017008083A (es) | Compuestos 2,3,4,5-tetrahidropiridin-6-amina y 3,4-dihidro-2h-pirrol-5-amina inhibidores de beta-secretasa. | |
| MX2019007100A (es) | Derivados de tiazina y oxazina biciclicos como inhibidores de beta-secretasa y metodos de uso. | |
| PT3894411T (pt) | Derivados da 7-fenoxi-n-(3-azabiciclo[3.2.1]octan-8-il)-6,7-dihidro-5h-pirrolo[1,2-b][1,2,4]triazol-2-amina e compostos relacionados enquanto moduladores da gama-secretase para o tratamento da doença de alzheimer | |
| MX2019007102A (es) | Derivados de tiazina como inhibidores de beta-secretasa y metodos de uso. | |
| PH12015502676A1 (en) | 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1h-pyrrol-3-yl)benzenesulfonamide as alpha 7 nachr modulator | |
| ECSP18006622A (es) | Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores de receptor muscarinico m1 cholinergico | |
| CA2863110A1 (en) | 1,2- pyridazine, 1,6- pyridazine or pyrimidine - benzamide derivatives as gpbar1 modulators | |
| PH12019502792A1 (en) | Tetrahydropyridopyrazine modulators of gpr6 | |
| TN2013000034A1 (en) | Heterocyclic compound and use thereof | |
| CL2015000442A1 (es) | Compuestos derivados de acilguanidinas espirociclicas, inhibidores de la actividad de la enzima beta-secretasa (bace1); compuestos intermediarios; composicion farmaceutica; y uso para tratar un trastorno o enfermedad seleccionado de alzheimer, trisomia 21 (sindrome de down), demencia senil, parkinson y glaucoma, entre otros. | |
| WO2012138254A3 (ru) | Производные 4,4 '-бифенил амидов, обладающие фармакологической активностью, и лекарственные средства на их основе |